Home Cart Sign in  
Chemical Structure| 104632-26-0 Chemical Structure| 104632-26-0

Structure of Pramipexole
CAS No.: 104632-26-0

Chemical Structure| 104632-26-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pramipexole is an agonist of dopamine receptors D2, D3, and D4 (Ki = 3.9, 2.2, 0.5, and 5.1 nM respectively) and it is indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pramipexole

CAS No. :104632-26-0
Formula : C10H17N3S
M.W : 211.33
SMILES Code : CCCN[C@H]1CCC2=C(C1)SC(N)=N2
MDL No. :MFCD00869076
InChI Key :FASDKYOPVNHBLU-ZETCQYMHSA-N
Pubchem ID :119570

Safety of Pramipexole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Pramipexole

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
primary astrocytes from Drd3 KO mice 50-200 μM 1 hour PPX failed to reduce the cleaved caspase-1 and IL-1β protein levels induced by ATP and LPS priming in astrocytes in the presence of lysosomal inhibitor CQ, implying the requirement of autophagy in PPX modulated inflammasome activation. Acta Pharmacol Sin. 2023 Jan;44(1):32-43.
primary mouse astrocytes 100-400 μM 24 h PPX dose-dependently enhanced the autophagy activity in the astrocytes evidenced by the elevations in LC3-II and BECN1 protein expression, as well as the increase of GFP-LC3 puncta formation. Acta Pharmacol Sin. 2023 Jan;44(1):32-43.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice LPS-induced Parkinson's disease model Intraperitoneal injection 0.5 mg/kg Administered 3 days before surgery and continued for 3 or 21 days after surgery PPX significantly alleviated the loss of DA neurons, and suppressed the astrocyte activation and levels of proinflammatory cytokine IL-1β in the substantia nigra of LPS-injected mice. Furthermore, PPX significantly decreased the expression of NLRP3 inflammasome-associated proteins in the striatum. Acta Pharmacol Sin. 2023 Jan;44(1):32-43.
C57BL/6 mice MPTP-induced Parkinson's disease model Oral 3 mg/kg Once daily for 18 days To evaluate the protective effects of Pramipexole on the MPTP-induced Parkinson's disease model. The results showed that Pramipexole protected mice against MPTP injuries, reduced the loss of dopaminergic neurons, and improved neurotransmitter levels, astrocyte activation, blood-brain barrier disruption, and other pathological changes. Acta Pharmacol Sin. 2017 Oct;38(10):1317-1328
Rats Parkinson's disease model Subcutaneous injection 0.3 mg/kg Once daily for 21 days To investigate the effects of pramipexole on behavioral flexibility, results showed that pramipexole significantly decreased behavioral flexibility, especially in lesioned rats. NPJ Parkinsons Dis. 2023 Mar 1;9(1):31
Mice Reserpine-induced fibromyalgia-like model Intraperitoneal injection 0.1, 1, and 5 mg/kg Once daily for 4 days Pramipexole significantly reduced reserpine-induced mechanical allodynia and thermal sensitivity, and decreased immobility time while increasing grooming behavior in the forced swimming test and splash test. Additionally, Pramipexole restored dopamine levels in the central nervous system and reduced oxidative stress. Neural Regen Res. 2022 Feb;17(2):450-458
Rats Highly impulsive rat model Intraperitoneal injection 0.2 mg/kg Once daily for 12 days Pramipexole significantly reduced impulsivity in highly impulsive rats, particularly under long inter-trial interval (LITI) conditions. In situ hybridization analysis revealed that pramipexole caused a decrease in Zif268 mRNA levels in various striatal regions, especially in the prefrontal cortex and nucleus accumbens core. Transl Psychiatry. 2024 Feb 9;14(1):86
Mice Severe Parkinson’s disease model induced by MPTP/paraquat Oral 1 mg/kg Once daily for eight weeks To evaluate the neuroprotective effects of Pramipexole in a severe Parkinson’s disease model induced by MPTP/paraquat, the results showed no improvement in neurodegeneration with Pramipexole therapy Ther Adv Neurol Disord. 2010 Nov;3(6):333-7

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01424163 Amyotrophic Lateral Sclerosis Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<
NCT02231294 - Completed - -
NCT01281189 Amyotrophic Lateral Sclerosis Phase 3 Completed - -
NCT03642964 Major Depressive Disorder (MDD... More >>) Less << Phase 2 Active, not recruiting January 30, 2019 United States, California ... More >> Collaborative Neuroscience Network Long Beach, California, United States, 90806 Less <<
NCT01711866 Advanced Idiopathic Parkinson'... More >>s Disease Less << Phase 4 Completed - United States, Alabama ... More >> 505 Anniston, Alabama, United States United States, Florida 506 Atlantis, Florida, United States 508 Miami Springs, Florida, United States United States, Georgia 502 Atlanta, Georgia, United States United States, Ohio 501 Dayton, Ohio, United States United States, Oklahoma 509 Oklahoma City, Oklahoma, United States Korea, Republic of 101 Busan, Korea, Republic of 102 Busan, Korea, Republic of 108 Daegu, Korea, Republic of 109 Daegu, Korea, Republic of 105 Gyeonggi-Do, Korea, Republic of 103 Seoul, Korea, Republic of 104 Seoul, Korea, Republic of 106 Seoul, Korea, Republic of 107 Seoul, Korea, Republic of Malaysia 202 Sarawak, Malaysia Singapore 401 Singapore, Singapore 403 Singapore, Singapore Taiwan 301 Linkou, Taiwan 304 Taichung, Taiwan 305 Taipei, Taiwan Less <<
NCT00274131 Parkinson Disease Phase 3 Completed - -
NCT01711866 - Completed - -
NCT00615914 - Completed - -
NCT00025792 Bipolar Disorder PHASE2 COMPLETED 2025-11-05 National Institute of Mental H... More >>ealth (NIMH), Bethesda, Maryland, 20892, United States Less <<
NCT00615914 - Completed - -
NCT00479401 Early Parkinson Disease (Early... More >> PD) Less << Phase 3 Completed - -
NCT01424176 Amyotrophic Lateral Sclerosis ... More >> Renal Insufficiency Less << Phase 1 Completed - United States, Florida ... More >> Research Site Orlando, Florida, United States, 32809 United States, Minnesota Research Site Brooklyn Center, Minnesota, United States, 55430 Less <<
NCT00479401 - Completed - -
NCT03683225 Idiopathic Parkinson Disease Phase 2 Not yet recruiting March 1, 2020 -
NCT00144209 Restless Legs Syndrome Phase 3 Completed - Switzerland ... More >> Boehringer Ingelheim Investigational Site Basel, Switzerland, 4025 Boehringer Ingelheim Investigational Site Basel, Switzerland, 4031 Boehringer Ingelheim Investigational Site Bern, Switzerland, 3000 Boehringer Ingelheim Investigational Site Lugano, Switzerland, CH-6900 Boehringer Ingelheim Investigational Site Zurich, Switzerland, 8091 Boehringer Ingelheim Investigational Site Zurzach, Switzerland, 5330 Less <<
NCT01622088 Amyotrophic Lateral Sclerosis Phase 3 Terminated(The Initial Phase 3... More >> Study (NCTO1281189) did not meet its primary efficacy endpoint.) Less << - -
NCT01511029 Amyotrophic Lateral Sclerosis Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT01525641 - Completed - -
NCT00804479 - Terminated(Funding for the CAL... More >>M-PD Cohort Study was terminated by sponsor.) Less << - United States, New York ... More >> University of Rochester Rochester, New York, United States, 14620 Less <<
NCT01525641 - Completed - -
NCT00240409 Parkinson Disease Phase 3 Completed - China ... More >> First Hospital of Beijing University Beijing, China, 100034 Beijing Tian Tan Hospital Beijing, China, 100050 Beijing Hospital Beijing, China, 100730 Peking Union Medical College Hospital Beijing, China, 100730 General Hospital of PLA Beijing, China, 100853 Shanghai Rui Jin Hospital Shanghai, China, 200025 Hua Shan Hospital, Fu Dan University Shanghai, China, 200040 Less <<
NCT01449578 Amyotrophic Lateral Sclerosis Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT01597310 Healthy Volunteers Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT02248207 Parkinson Disease COMPLETED - -
NCT00721279 - Completed - -
NCT02233023 Parkinson Disease Phase 4 Completed - -
NCT02236741 - Completed - -
NCT02025608 Restless Legs Syndrome Phase 4 Completed - Switzerland ... More >> Neurocenter of Southern Switzerland Lugano, Ticino, Switzerland, 6903 Department of Neurology, Inselspital Bern, Switzerland, 3010 Less <<
NCT00681863 Tourette Syndrome Phase 3 Terminated(Terminated for slow... More >> enrollment.) Less << - United States, Florida ... More >> 248.642.0026 Boehringer Ingelheim Investigational Site Bradenton, Florida, United States 248.642.0025 Boehringer Ingelheim Investigational Site Tampa, Florida, United States United States, Georgia 248.642.0006 Boehringer Ingelheim Investigational Site Columbus, Georgia, United States United States, Massachusetts 248.642.0005 Boehringer Ingelheim Investigational Site Cambridge, Massachusetts, United States United States, New York 248.642.0003 Boehringer Ingelheim Investigational Site Manhasset, New York, United States 248.642.0009 Boehringer Ingelheim Investigational Site New York, New York, United States 248.642.0018 Boehringer Ingelheim Investigational Site New York, New York, United States 248.642.0013 Boehringer Ingelheim Investigational Site Orangeburg, New York, United States United States, Oklahoma 248.642.0029 Boehringer Ingelheim Investigational Site Oklahoma City, Oklahoma, United States United States, Rhode Island 248.642.0010 Boehringer Ingelheim Investigational Site Providence, Rhode Island, United States United States, Tennessee 248.642.0030 Boehringer Ingelheim Investigational Site Memphis, Tennessee, United States United States, Texas 248.642.0008 Boehringer Ingelheim Investigational Site Houston, Texas, United States United States, Virginia 248.642.0023 Boehringer Ingelheim Investigational Site Norfolk, Virginia, United States Germany 248.642.49004 Boehringer Ingelheim Investigational Site Ulm, Germany Less <<
NCT00721279 - Completed - -
NCT00086307 Major Depression Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00681863 - Terminated(Terminated for slow... More >> enrollment.) Less << - -
NCT00086307 - Completed - -
NCT02262546 Healthy Phase 1 Completed - -
NCT00152997 Restless Legs Syndrome Phase 2 Completed - Japan ... More >> Boehringer Ingelheim Investigational Site Akita, Akita, Japan Boehringer Ingelheim Investigational Site Kochi, Kochi, Japan Boehringer Ingelheim Investigational Site Kurume, Fukuoka, Japan Boehringer Ingelheim Investigational Site Otaru,Hokkaido, Japan Boehringer Ingelheim Investigational Site Sakai, Osaka, Japan Boehringer Ingelheim Investigational Site Shibuya,Tokyo, Japan Boehringer Ingelheim Investigational Site Takatsuki, Osaka, Japan Less <<
NCT01097421 - Completed - -
NCT00596115 - - - -
NCT00152958 Restless Legs Syndrome PHASE3 COMPLETED - Clinpharm International GmbH &... More >> Co. KG, Berlin (Hellersdorf), Germany|Boehringer Ingelheim Investigational Site, Berlin, Germany|Charité Campus Virchow-Klinikum, Berlin, Germany|emovis GmbH, Berlin, Germany|Boehringer Ingelheim Investigational Site, Chemnitz, Germany|ClinPharm Internat. GmbH & Co. KG, G?rlitz, Germany|Paracelsus-Elena-Klinik, Kassel, Germany|ClinPharm International GmbH & Co. KG, Leipzig, Germany|Neurologische Klinik der Otto-von-Guericke-Universit?t, Magdeburg, Germany|Universit?tsklinikum Giessen und Marburg, Marburg, Germany|Boehringer Ingelheim Investigational Site, München, Germany|Boehringer Ingelheim Investigational Site, Würzburg, Germany Less <<
NCT00597896 Bipolar Disorder Phase 4 Completed - United States, New York ... More >> North Shore - Long Island Jewish Health System Glen Oaks, New York, United States, 11004 Less <<
NCT01097421 - Completed - -
NCT00597896 - Completed - -
NCT00133198 Restless Legs Syndrome PHASE3 COMPLETED 2025-02-05 Pivotal Research Centers, Peor... More >>ia, Arizona, 85381, United States|Mayo Clinic - Scottsdale, Scottsdale, Arizona, 85259, United States|Boehringer Ingelheim Investigational Site, Fountain Valley, California, 92708, United States|HealthQuest Clinical Trials Research, San Diego, California, 92123, United States|Stanford Sleep Clinic, Stanford, California, 94305-5730, United States|Adult CF Center, Denver, Colorado, 80206, United States|University of Colorado Health Sciences Center, Denver, Colorado, 80262, United States|CNI Movement Disorders Center, Englewood, Colorado, 80113, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, 20037, United States|PAB Clinical Research, Brandon, Florida, 33511, United States|Broward Research Group, Pembroke Pines, Florida, 33026-1956, United States|Clinical Research Group of St Petersburg, St.Petersburg, Florida, 33707, United States|Cleveland Clinic Florida- Department of Neurology, Weston, Florida, 33331, United States|5671 Peachtree Dunwoody Road, Atlanta, Georgia, 30342, United States|Atlanta Pulmonary Group, LLC, Atlanta, Georgia, 30342, United States|Movement Disorders Clinic, Augusta, Georgia, 30912, United States|Sleepmed, Inc, Macon, Georgia, 31201, United States|University of Iowa Health Care, Iowa City, Iowa, 52242-1053, United States|Mid America NeuroScience Institute, Lenexa, Kansas, 66214, United States|Boehringer Ingelheim Investigational Site, Baton Rouge, Louisiana, 70808, United States|Center for Sleep and Wake Disorders, Chevy Chase, Maryland, 20815, United States|170 Thomas Johnson Dr, Suite 100, Frederick, Maryland, 21702, United States|Sleep Health Centers, Newton Center, Massachusetts, 02459, United States|Henry Ford Hospital - Sleep Disorders and Research Center, Detroit, Michigan, 48202, United States|Hennepin County Medical Center, Minneapolis, Minnesota, 55415, United States|Sleep Disorders Center, Jackson, Mississippi, 39216, United States|Sleep Medicine Center, St.Louis, Missouri, 63108, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, 87108, United States|Winthrop Sleep Disorders Center, Mineola, New York, 11501, United States|932 Morreene Road #264, Durham, North Carolina, 27705, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Wilmington Health Associates, Wilmington, North Carolina, 28401, United States|Attn: Dr. David Mayleben, Cincinnati, Ohio, 45219, United States|Metrohealth Medical Center, Cleveland, Ohio, 44109, United States|Ohio Sleep Medicine Institute, Dublin, Ohio, 43017, United States|Attn: Controller/Grants & Contracts Accounting, Oklahoma City, Oklahoma, 73190-3046, United States|Center For Sleep Medicine, Lafayette Hill, Pennsylvania, 19444, United States|The Arthritis Group, Philadelphia, Pennsylvania, 19152, United States|Boehringer Ingelheim Investigational Site, Columbia, South Carolina, 29201, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Sleep Associates, Plano, Texas, 75093, United States|1500 N. Bearegard St, #300, Alexandria, Virginia, 22311, United States|Lynchburg Pulmonary Associates, Inc., Lynchburg, Virginia, 24501, United States|Eastern Virginia Medical School, Norfolk, Virginia, 23507, United States Less <<
NCT00144300 Parkinson Disease Phase 4 Completed - -
NCT00647296 Amyotrophic Lateral Sclerosis Phase 2 Completed - -
NCT00349531 Restless Legs Syndrome PHASE4 COMPLETED - 248.615.45103 Boehringer Ingel... More >>heim Investigational Site, Kgs. Lyngby, Denmark|248.615.45102 Boehringer Ingelheim Investigational Site, K?benhavn K, Denmark|248.615.45101 Boehringer Ingelheim Investigational Site, K?benhavn NV, Denmark|248.615.45104 Boehringer Ingelheim Investigational Site, Vaerl?se, Denmark|248.615.35101 Boehringer Ingelheim Investigational Site, Espoo, Finland|248.615.35104 Boehringer Ingelheim Investigational Site, Joensuu, Finland|248.615.35103 Boehringer Ingelheim Investigational Site, Lahti, Finland|248.615.35102 Boehringer Ingelheim Investigational Site, Oulu, Finland|248.615.49103 Boehringer Ingelheim Investigational Site, Berlin-Steglitz, Germany|248.615.49109 Boehringer Ingelheim Investigational Site, Berlin, Germany|248.615.49105 Boehringer Ingelheim Investigational Site, G?rlitz, Germany|248.615.49108 Boehringer Ingelheim Investigational Site, Hattingen, Germany|248.615.49106 Boehringer Ingelheim Investigational Site, München, Germany|248.615.49102 Boehringer Ingelheim Investigational Site, Schwerin, Germany|248.615.49101 Boehringer Ingelheim Investigational Site, Ulm, Germany|248.615.49107 Boehringer Ingelheim Investigational Site, Witten, Germany|248.615.49104 Boehringer Ingelheim Investigational Site, Würzburg, Germany|248.615.35302, BIrr, Ireland|248.615.35301 Boehringer Ingelheim Investigational Site, Carrigtwohill, Ireland|248.615.35303, Castlecomer, Ireland|248.615.39007 Policlinico di Bari - Università di Bari, Bari, Italy|248.615.39006 Ospedale Civile di Dolo, Dolo (VE), Italy|248.615.39002 Ospedale S. Martino - A. O. Università di Genova, Genova, Italy|248.615.39008 Policlinico Gaetano Martino, Messina, Italy|248.615.39001 Istituto San Raffaele Turro, Milano, Italy|248.615.39004 IRCCS Fondazione Istituto Neurologico "C. Mondino", Pavia, Italy|248.615.39005 Ospedale S. Chiara, Pisa, Italy|248.615.39003 A. O. Santa Maria della Misericordia, Udine, Italy|248.615.47101 Boehringer Ingelheim Investigational Site, Bekkestua, Norway|248.615.47102 Boehringer Ingelheim Investigational Site, Fevik, Norway|248.615.47104 Boehringer Ingelheim Investigational Site, Moelv, Norway|248.615.47103 Boehringer Ingelheim Investigational Site, Oslo, Norway|248.615.47105 Boehringer Ingelheim Investigational Site, Tvedestrand, Norway|248.615.3408 Hospital Nuestra Se?ora de Sonsoles, Avila, Spain|248.615.3402, Maderid, Spain|248.615.3404 Hospital General Universitario Gregorio Mara?ón, Madrid, Spain|248.615.3406, Madrid, Spain|248.615.3407, Madrid, Spain|248.615.3403 Hospital General de Catalunya, San Cugat del Valles (Barcelona), Spain|248.615.46101 Boehringer Ingelheim Investigational Site, G?teborg, Sweden|248.615.46103 Boehringer Ingelheim Investigational Site, G?teborg, Sweden|248.615.46102 Boehringer Ingelheim Investigational Site, Hedemora, Sweden|248.615.46104 Boehringer Ingelheim Investigational Site, ?rebro, Sweden|248.615.44006 Boehringer Ingelheim Investigational Site, Buckshaw Village, Chorley, United Kingdom|248.615.44004 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom|248.615.44007 Boehringer Ingelheim Investigational Site, Manchester, United Kingdom|248.615.44009 Boehringer Ingelheim Investigational Site, Reading, United Kingdom|248.615.44002 Boehringer Ingelheim Investigational Site, Romford, United Kingdom|248.615.44005 Boehringer Ingelheim Investigational Site, West Green, Crawley, United Kingdom Less <<
NCT01320982 Schizophrenia ... More >> Schizoaffective Disorder Less << Phase 3 Unknown July 2012 Israel ... More >> Sheba Medical Center Not yet recruiting Ramat-Gan, Israel, 52621 Contact: Mark Weiser, MD    +972-52-6666575    mweiser@netvision.net.il    Contact: Katya Rubinstein, MA    +972-3-5303454    rubins.katya@gmail.com    Principal Investigator: Mark Weiser, MD          Romania Clinica de Psihiatrie Not yet recruiting Arad, Romania Contact: Delia Podea, MD    0722 583 757    deliapodea@gmail.com    Principal Investigator: Delia Podea, MD          Spitalul de Psihiatrie Botosani, Sectia Psihiatrie Not yet recruiting Botosani, Romania Contact: Nicolae Vlad, MD    0741 335 034    v_nicolae@yahoo.com    Principal Investigator: Nicolae Vlad, MD          Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Dan Prelipceanu, MD    0722 300 227    prelipceanudan@yahoo.com    Principal Investigator: Dan Prelipceanu, MD          Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Gabriela Marian, MD    0723 569 620    gabi.marian@yahoo.com    Principal Investigator: Marian Gabriela, MD          Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Maria Ladea, MD    0724 371 042    marialadea@gmail.com    Principal Investigator: Maria Ladea, MD          Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Dorina-Valerica Sima, MD    0723 859 570    dorinasima@yahoo.com    Principal Investigator: Dorina-Valerica Sima, MD          Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Maria-Silvia Trandafir, MD    0724 275 572    silviatrandafir2004@yahoo.com    Principal Investigator: Maria-Silvia Trandafir, MD          Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Ana-Liana Giurgiuca, MD    0722 378 967    giurgiuca_liana@yahoo.com    Principal Investigator: Ana-Liana Giurgiuca, Md          Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia" Not yet recruiting Bucuresti, Romania Contact: Valentin Matei, MD    0723 640 918    petcu_camelia@yahoo.com    Principal Investigator: Valentin Matei, MD          Sp. Jud. "Prof. Dr.O. Fodor" Not yet recruiting Cluj-Napoca, Romania Contact: Mircea-Alexandru Birt, MD    0721 012 220    mirceabirt@yahoo.com    Principal Investigator: Mircea-Alexandru Birt, MD          Spitalul Clinic Judetean de Urgenta Cluj Not yet recruiting Cluj-Napoca, Romania Contact: Ioana-Valentina Miclutia, MD    0722 796 067    ioanamiclu@yahoo.com    Principal Investigator: Ioana-Valentina Miclutia, MD          Spitalul Clinic de Psihiatrie Socola, Iasi Not yet recruiting Iasi, Romania Contact: Serban Turliuc, MD    0745 203 002    serban_turliuc@yahoo.com    Principal Investigator: Serban Turliuc, MD          Spitalul Clinic de Psihiatrie Socola, Iasi Not yet recruiting Iasi, Romania Contact: Nicoleta Cartas, MD    0724 576 261    nicoletacartas_socola@yahoo.com    Principal Investigator: Nicoleta Cartas, MD Less <<
NCT00651183 - Completed - -
NCT00651183 - Completed - -
NCT00144300 - Completed - -
NCT01170091 - Completed - Korea, Republic of ... More >> Boehringer Ingelheim Investigational Site 1 Busan, Korea, Republic of Boehringer Ingelheim Investigational Site 2 Busan, Korea, Republic of Boehringer Ingelheim Investigational Site 3 Busan, Korea, Republic of Boehringer Ingelheim Investigational Site 32 Daegu, Korea, Republic of Boehringer Ingelheim Investigational Site 33 Daegu, Korea, Republic of Boehringer Ingelheim Investigational Site 34 Daejeon, Korea, Republic of Boehringer Ingelheim Investigational Site 35 Daejeon, Korea, Republic of Boehringer Ingelheim Investigational Site 36 Deajeon, Korea, Republic of Boehringer Ingelheim Investigational Site 25 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 26 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 27 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 28 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 29 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 30 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 31 Gwangju, Korea, Republic of Boehringer Ingelheim Investigational Site 10 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 11 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 12 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 13 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 14 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 15 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 16 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 17 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 18 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 19 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 20 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 21 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 22 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 23 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 24 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 4 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 5 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 6 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 7 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 8 Seoul, Korea, Republic of Boehringer Ingelheim Investigational Site 9 Seoul, Korea, Republic of Less <<
NCT00275457 Restless Legs Syndrome Phase 3 Completed - Austria ... More >> Univ.-Klinik für Neurologie Graz, Austria, 8036 Univ.-Klinik für Neurologie Innsbruck, Austria, 6020 AKH der Stadt Linz Linz, Austria, 4021 Confraternität Privatklinik Wien, Austria, 1080 AKH Universitätsklinik für Psychiatrie Wien, Austria, 1090 Sonderkrankenanstalt für neurologischen und Wien, Austria, 1130 Wilhelminenspital der Stadt Wien Wien, Austria, 1160 Germany Boehringer Ingelheim Investigational Site Bad Dürrheim-Sunthausen, Germany, 78073 Boehringer Ingelheim Investigational Site Bad Krozingen, Germany, 79189 Boehringer Ingelheim Investigational Site Berlin, Germany, 10625 emovis GmbH Berlin, Germany, 10629 Facharzt für Neurologie Emmendingen, Germany, 79312 Boehringer Ingelheim Investigational Site Kehl, Germany, 77694 ClinPharm International GmbH & Co. KG Leipzig, Germany, 04229 Universitätsklinikum Giessen und Marburg Marburg, Germany, 35039 Netherlands Boehringer Ingelheim Investigational Site Beek en Donk, Netherlands, 5741 AR Boehringer Ingelheim Investigational Site Den Haag, Netherlands, 2585 LJ Boehringer Ingelheim Investigational Site Deurne, Netherlands, 5751 XJ Boehringer Ingelheim Investigational Site Ewijk, Netherlands, 6644 CL Boehringer Ingelheim Investigational Site Lichtenvoorde, Netherlands, 7131 CM Boehringer Ingelheim Investigational Site Rijswijk, Netherlands, 2281 AK Boehringer Ingelheim Investigational Site Roelofarendsveen, Netherlands, 2371 RB Boehringer Ingelheim Investigational Site Rotterdam, Netherlands, 3082 DC Norway Boehringer Ingelheim Investigational Site Hamar, Norway, N-2317 Boehringer Ingelheim Investigational Site Oslo, Norway, N-0159 Boehringer Ingelheim Investigational Site Oslo, Norway, N-0303 Boehringer Ingelheim Investigational Site Tønsberg, Norway, N-3111 Sweden Boehringer Ingelheim Investigational Site Göteborg, Sweden, 413 45 Stockholms Neuro Center Stockholm, Sweden, 112 81 Neurologkliniken Stockholm, Sweden, 141 86 Boehringer Ingelheim Investigational Site Uppsala, Sweden, 751 85 Läkarhuset Vällingby Vällingby, Sweden, 162 68 Boehringer Ingelheim Investigational Site Västra Frölunda, Sweden, 421 30 Boehringer Ingelheim Investigational Site Örebro, Sweden, 701 85 Less <<
NCT00239486 Restless Legs Syndrome PHASE2 COMPLETED 2025-04-04 NEURO, Helsinki, FIN-00250, Fi... More >>nland Less <<
NCT01170091 - Completed - -
NCT00356096 Restless Legs Syndrome ... More >> Depression Less << Phase 4 Completed - -
NCT00140218 Amyotrophic Lateral Sclerosis Phase 1 Phase 2 Completed - United States, Pennsylvania ... More >> David Lacomis MD Pittsburgh, Pennsylvania, United States United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908 Less <<
NCT00375284 Restless Legs Syndrome PHASE4 COMPLETED - 248.616.065 Boehringer Ingelhe... More >>im Investigational Site, Birmingham, Alabama, United States|248.616.028 Boehringer Ingelheim Investigational Site, Dothan, Alabama, United States|248.616.035 Boehringer Ingelheim Investigational Site, Mesa, Arizona, United States|248.616.025 Boehringer Ingelheim Investigational Site, Peoria, Arizona, United States|248.616.073 Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States|248.616.067 Boehringer Ingelheim Investigational Site, Tucson, Arizona, United States|248.616.009 Boehringer Ingelheim Investigational Site, Fayetteville, Arkansas, United States|248.616.040 Boehringer Ingelheim Investigational Site, Foothill Ranch, California, United States|248.616.062 Boehringer Ingelheim Investigational Site, Fullerton, California, United States|248.616.050 Boehringer Ingelheim Investigational Site, Pasadena, California, United States|248.616.031 Boehringer Ingelheim Investigational Site, Colorado Springs, Colorado, United States|248.616.017 Boehringer Ingelheim Investigational Site, Pueblo, Colorado, United States|248.616.071 Boehringer Ingelheim Investigational Site, Wallingford, Connecticut, United States|248.616.043 Boehringer Ingelheim Investigational Site, Deland, Florida, United States|248.616.014 Boehringer Ingelheim Investigational Site, Jacksonville, Florida, United States|248.616.020 Boehringer Ingelheim Investigational Site, Naples, Florida, United States|248.616.048 Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|248.616.072 Boehringer Ingelheim Investigational Site, Spring Hill, Florida, United States|248.616.018 Boehringer Ingelheim Investigational Site, St. Petersburg, Florida, United States|248.616.049 Boehringer Ingelheim Investigational Site, Augusta, Georgia, United States|248.616.033 Boehringer Ingelheim Investigational Site, Columbus, Georgia, United States|248.616.057 Boehringer Ingelheim Investigational Site, Macon, Georgia, United States|248.616.066 Boehringer Ingelheim Investigational Site, Savannah, Georgia, United States|248.616.047 Boehringer Ingelheim Investigational Site, Stockbridge, Georgia, United States|248.616.059 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|248.616.045 Boehringer Ingelheim Investigational Site, Lenexa, Kansas, United States|248.616.061 Boehringer Ingelheim Investigational Site, Olathe, Kansas, United States|248.616.060 Boehringer Ingelheim Investigational Site, Baton Rouge, Louisiana, United States|248.616.058 Boehringer Ingelheim Investigational Site, Brighton, Massachusetts, United States|248.616.051 Boehringer Ingelheim Investigational Site, Wellesley Hills, Massachusetts, United States|248.616.001 Boehringer Ingelheim Investigational Site, Minneapolis, Minnesota, United States|248.616.004 Boehringer Ingelheim Investigational Site, Jackson, Mississippi, United States|248.616.064 Boehringer Ingelheim Investigational Site, Florissant, Missouri, United States|248.616.016 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States|248.616.063 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States|248.616.053 Boehringer Ingelheim Investigational Site, Dover, New Hampshire, United States|248.616.036 Boehringer Ingelheim Investigational Site, Albuquerque, New Mexico, United States|248.616.021 Boehringer Ingelheim Investigational Site, Albany, New York, United States|248.616.013 Boehringer Ingelheim Investigational Site, Cincinnati, Ohio, United States|248.616.003 Boehringer Ingelheim Investigational Site, Cleveland, Ohio, United States|248.616.068 Boehringer Ingelheim Investigational Site, Marion, Ohio, United States|248.616.012 Boehringer Ingelheim Investigational Site, Norman, Oklahoma, United States|248.616.006 Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States|248.616.019 Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States|248.616.069 Boehringer Ingelheim Investigational Site, Clarks Summit, Pennsylvania, United States|248.616.008 Boehringer Ingelheim Investigational Site, Columbia, South Carolina, United States|248.616.005 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|248.616.070 Boehringer Ingelheim Investigational Site, Rockwall, Texas, United States|248.616.039 Boehringer Ingelheim Investigational Site, San Marcos, Texas, United States|248.616.011 Boehringer Ingelheim Investigational Site, Alexandria, Virginia, United States|248.616.055 Boehringer Ingelheim Investigational Site, Norfolk, Virginia, United States|248.616.024 Boehringer Ingelheim Investigational Site, Milwaukee, Wisconsin, United States Less <<
NCT02172573 Parkinson Disease Phase 3 Completed - -
NCT00558467 Tourette Syndrome Phase 2 Completed - United States, Florida ... More >> 248.644.0026 Boehringer Ingelheim Investigational Site Bradenton, Florida, United States 248.644.0025 Boehringer Ingelheim Investigational Site Tampa, Florida, United States United States, Georgia 248.644.0006 Boehringer Ingelheim Investigational Site Columbus, Georgia, United States United States, Illinois 248.644.0012 Boehringer Ingelheim Investigational Site Chicago, Illinois, United States United States, Massachusetts 248.644.0005 Boehringer Ingelheim Investigational Site Cambridge, Massachusetts, United States United States, New York 248.644.0003 Boehringer Ingelheim Investigational Site Manhasset, New York, United States 248.644.0009 Boehringer Ingelheim Investigational Site New York, New York, United States 248.644.0018 Boehringer Ingelheim Investigational Site New York, New York, United States 248.644.0013 Boehringer Ingelheim Investigational Site Orangeburg, New York, United States United States, Oklahoma 248.644.0029 Boehringer Ingelheim Investigational Site Oklahoma City, Oklahoma, United States United States, Rhode Island 248.644.0010 Boehringer Ingelheim Investigational Site Providence, Rhode Island, United States United States, Tennessee 248.644.0030 Boehringer Ingelheim Investigational Site Memphis, Tennessee, United States United States, Texas 248.644.0008 Boehringer Ingelheim Investigational Site Houston, Texas, United States United States, Virginia 248.644.0023 Boehringer Ingelheim Investigational Site Norfolk, Virginia, United States Germany 248.644.49001 Boehringer Ingelheim Investigational Site Hannover, Germany 248.644.49004 Boehringer Ingelheim Investigational Site Ulm, Germany Less <<
NCT01515774 Parkinson's Disease Phase 4 Unknown October 2012 Korea, Republic of ... More >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 110-744 Contact: Beom S. Jeon, MD, PhD    82-2-2072-2876    brain@snu.ac.kr    Contact: Ji Y Yun, MD    82-2-2072-0359    dream-yoon@hanmail.net    Principal Investigator: Beom S. Jeon, MD, PhD          Sub-Investigator: Han-Joon Kim, MD          Sub-Investigator: Ji Y Yun, MD          Sub-Investigator: Young Eun Kim, MD Less <<
NCT01607034 Healthy Volunteers Phase 1 Completed - United States, Minnesota ... More >> Research Site St. Paul, Minnesota, United States Less <<
NCT00558467 - Completed - -
NCT02033369 Major Depressive Disorder PHASE4 COMPLETED 2025-07-17 New York State Psychiatric Ins... More >>titute, New York, New York, 10032, United States Less <<
NCT00472199 Restless Legs Syndrome Phase 4 Completed - -
NCT00893841 Bipolar Depression Phase 2 Completed - United States, California ... More >> Affiliated Research Institute San Diego, California, United States, 92108 United States, Washington Eastside Therapeutic Resource Kirkland, Washington, United States, 98033 Canada, Alberta Dr. P. Chokka Edmonton, Alberta, Canada, T6L 6W6 Canada, British Columbia Penticton Regional Penticton, British Columbia, Canada, V2A 4M4 Copeman Neuroscience Centre Vancouver, British Columbia, Canada, V6Z 2L4 Canada, Nova Scotia AK Munshi Medical Inc. Sydney, Nova Scotia, Canada, B1S 2E8 Canada, Ontario Regional Mental Health Care - London London, Ontario, Canada, N6A 4H1 Canada, Quebec Hôpital Louis-H.Lafontaine Montreal, Quebec, Canada, H1N 3M5 Canada Clinique Marie Fitzbach Quebec, Canada, G1R 2W8 Less <<
NCT02033369 Major Depressive Disorder PHASE4 COMPLETED 2025-07-17 New York State Psychiatric Ins... More >>titute, New York, New York, 10032, United States Less <<
NCT02231918 Restless Legs Syndrome Phase 2 Completed - -
NCT02231918 - Completed - -
NCT00344994 Restless Legs Syndrome Phase 4 Completed - United States, Georgia ... More >> Medical College of Georgia Augusta, Georgia, United States, 30912 Less <<
NCT00402233 Parkinson Disease Phase 4 Completed - -
NCT00297778 - Completed - -
NCT00297778 Parkinson Disease ... More >> Depression Less << Phase 4 Completed - -
NCT00991276 Restless Legs Syndrome Phase 3 Completed - -
NCT00402233 - Completed - -
NCT01214109 Healthy Phase 1 Completed - China ... More >> 248.665.86002 Boehringer Ingelheim Investigational Site Beijing, China Less <<
NCT00231959 Depression Phase 4 Completed - United States, Massachusetts ... More >> Depression Clinical and Research Program, Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Less <<
NCT00472199 - Completed - -
NCT02248168 Parkinson Disease COMPLETED - -
NCT02260024 Healthy Phase 1 Completed - -
NCT02231905 Parkinson Disease Phase 4 Completed - -
NCT00991276 - Completed - -
NCT01191944 Parkinson Disease Phase 3 Completed - China ... More >> 248.671.86004 Boehringer Ingelheim Investigational Site Beijing, China 248.671.86006 Boehringer Ingelheim Investigational Site Beijing, China 248.671.86007 Boehringer Ingelheim Investigational Site Beijing, China 248.671.86020 Boehringer Ingelheim Investigational Site Beijing, China 248.671.86012 Boehringer Ingelheim Investigational Site Chengdu, China 248.671.86013 Boehringer Ingelheim Investigational Site Chongqing, China 248.671.86014 Boehringer Ingelheim Investigational Site Chongqing, China 248.671.86008 Boehringer Ingelheim Investigational Site Guangzhou, China 248.671.86009 Boehringer Ingelheim Investigational Site Guangzhou, China 248.671.86017 Boehringer Ingelheim Investigational Site Hangzhou, China 248.671.86018 Boehringer Ingelheim Investigational Site Hangzhou, China 248.671.86005 Boehringer Ingelheim Investigational Site Jinan, China 248.671.86002 Boehringer Ingelheim Investigational Site Nanjing, China 248.671.86001 Boehringer Ingelheim Investigational Site Shanghai, China 248.671.86003 Boehringer Ingelheim Investigational Site Shanghai, China 248.671.86010 Boehringer Ingelheim Investigational Site Shanghai, China 248.671.86011 Boehringer Ingelheim Investigational Site Shenyang, China 248.671.86019 Boehringer Ingelheim Investigational Site Suzhou, China 248.671.86015 Boehringer Ingelheim Investigational Site Wuhan, China 248.671.86016 Boehringer Ingelheim Investigational Site Wuhan, China Less <<
NCT01191944 - Completed - -
NCT00275275 Parkinson Disease Phase 3 Completed - United States, Kansas ... More >> University of Kansas Medical Center Kansas City, Kansas, United States, 66160 Less <<
NCT00654498 - Completed - -
NCT01214109 - Completed - -
NCT03329508 Parkinson Disease Phase 3 Recruiting December 30, 2019 -
NCT00275275 - Completed - -
NCT02177357 Parkinson Disease Phase 3 Completed - -
NCT00689052 Fibromyalgia Phase 2 Terminated - -
NCT00689052 - Terminated - -
NCT01536249 Amyotrophic Lateral Sclerosis Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT00654498 Restless Legs Syndrome Phase 3 Completed - China ... More >> 248.630.04 Boehringer Ingelheim Investigational Site Beijing, China 248.630.05 Boehringer Ingelheim Investigational Site Beijing, China 248.630.06 Boehringer Ingelheim Investigational Site Beijing, China 248.630.07 Boehringer Ingelheim Investigational Site Beijing, China 248.630.08 Boehringer Ingelheim Investigational Site Beijing, China 248.630.15 Boehringer Ingelheim Investigational Site Guangzhou, China 248.630.14 Boehringer Ingelheim Investigational Site Haerbin, China 248.630.10 Boehringer Ingelheim Investigational Site Hangzhou, China 248.630.09 Boehringer Ingelheim Investigational Site Nanjing, China 248.630.12 Boehringer Ingelheim Investigational Site Qingdao, China 248.630.01 Boehringer Ingelheim Investigational Site Shanghai, China 248.630.02 Boehringer Ingelheim Investigational Site Shanghai, China 248.630.03 Boehringer Ingelheim Investigational Site Shanghai, China 248.630.16 Boehringer Ingelheim Investigational Site Suzhou, China 248.630.13 Boehringer Ingelheim Investigational Site Wuhan, China 248.630.11 Boehringer Ingelheim Investigational Site Xian, Shanxi Province, China Less <<
NCT02261103 Healthy Phase 1 Completed - -
NCT02264132 Healthy Phase 1 Completed - -
NCT00390689 - Completed - -
NCT00321854 - Completed - -
NCT00321854 Parkinson Disease Phase 4 Completed - -
NCT00560508 Parkinson Disease Phase 2 Phase 3 Completed - Japan ... More >> 248.610.019 Boehringer Ingelheim Investigational Site Akashi, Hyogo, Japan 248.610.020 Boehringer Ingelheim Investigational Site Akita, Akita, Japan 248.610.006 Boehringer Ingelheim Investigational Site Aomori, Aomori, Japan 248.610.017 Boehringer Ingelheim Investigational Site Asahikawa, Hokkaido, Japan 248.610.018 Boehringer Ingelheim Investigational Site Asahikawa, Hokkaido, Japan 248.610.001 Boehringer Ingelheim Investigational Site Bunkyo-ku, Tokyo, Japan 248.610.014 Boehringer Ingelheim Investigational Site Fuchu, Tokyo, Japan 248.610.011 Boehringer Ingelheim Investigational Site Fukuoka, Fukuoka, Japan 248.610.015 Boehringer Ingelheim Investigational Site Iwamizawa,Hokkaido, Japan 248.610.003 Boehringer Ingelheim Investigational Site Kodaira, Tokyo, Japan 248.610.008 Boehringer Ingelheim Investigational Site Kyoto, Kyoto, Japan 248.610.021 Boehringer Ingelheim Investigational Site Kyoto, Kyoto, Japan 248.610.010 Boehringer Ingelheim Investigational Site Morioka, Iwate, Japan 248.610.005 Boehringer Ingelheim Investigational Site Okayama, Okayama, Japan 248.610.012 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 248.610.004 Boehringer Ingelheim Investigational Site Sagamihara, Kanagawa, Japan 248.610.009 Boehringer Ingelheim Investigational Site Shimogyo-ku, Kyoto, Kyoto, Japan 248.610.007 Boehringer Ingelheim Investigational Site Shiroishi, Miyagi, Japan 248.610.002 Boehringer Ingelheim Investigational Site Takamatsu, Kagawa, Japan Less <<
NCT02248155 Restless Legs Syndrome COMPLETED - -
NCT00390689 Idiopathic Restless Legs Syndr... More >>ome Less << Phase 3 Completed - Japan ... More >> 248.627.037 Boehringer Ingelheim Investigational Site Aichi-gun, Aichi, Japan 248.627.014 Boehringer Ingelheim Investigational Site Fujisawa, Kanagawa, Japan 248.627.029 Boehringer Ingelheim Investigational Site Fukuoka, Fukuoka, Japan 248.627.032 Boehringer Ingelheim Investigational Site Hiroshima, Hiroshima, Japan 248.627.030 Boehringer Ingelheim Investigational Site Kagoshima, Kagoshima, Japan 248.627.013 Boehringer Ingelheim Investigational Site Kanagawa, Yokohama, Japan 248.627.033 Boehringer Ingelheim Investigational Site Kanazawa, Ishikawa, Japan 248.627.027 Boehringer Ingelheim Investigational Site Kawasaki, Kanagawa, Japan 248.627.023 Boehringer Ingelheim Investigational Site Kitakyusyu, Fukuoka, Japan 248.627.024 Boehringer Ingelheim Investigational Site Kitakyusyu, Fukuoka, Japan 248.627.022 Boehringer Ingelheim Investigational Site Kochi, Kochi, Japan 248.627.034 Boehringer Ingelheim Investigational Site Kodaira, Tokyo, Japan 248.627.038 Boehringer Ingelheim Investigational Site Koriyama, Fukushima, Japan 248.627.041 Boehringer Ingelheim Investigational Site Koriyama, Fukushima, Japan 248.627.039 Boehringer Ingelheim Investigational Site Kumamoto, Kumamoto, Japan 248.627.003 Boehringer Ingelheim Investigational Site Kurume, Fukuoka, Japan 248.627.036 Boehringer Ingelheim Investigational Site Minato-ku, Tokyo, Japan 248.627.025 Boehringer Ingelheim Investigational Site Mitaka-shi, Tokyo, Japan 248.627.015 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 248.627.017 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 248.627.011 Boehringer Ingelheim Investigational Site Otaru, Hokkaido, Japan 248.627.026 Boehringer Ingelheim Investigational Site Otsu, Shiga, Japan 248.627.002 Boehringer Ingelheim Investigational Site Sakai,Osaka, Japan 248.627.010 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 248.627.035 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 248.627.012 Boehringer Ingelheim Investigational Site Sendai, Miyagi, Japan 248.627.001 Boehringer Ingelheim Investigational Site Shibuya-ku, Tokyo, Japan 248.627.004 Boehringer Ingelheim Investigational Site Shimotsuga-gun,Tochigi, Japan 248.627.040 Boehringer Ingelheim Investigational Site Shinjuku-ku, Tokyo, Japan 248.627.018 Boehringer Ingelheim Investigational Site Takatsuki,Osaka, Japan 248.627.028 Boehringer Ingelheim Investigational Site Tokorozawa, Saitama, Japan 248.627.019 Boehringer Ingelheim Investigational Site Tokushima, Tokushima, Japan 248.627.016 Boehringer Ingelheim Investigational Site Toyohashi, Aichi, Japan 248.627.031 Boehringer Ingelheim Investigational Site Urasoe, Okinawa, Japan Less <<
NCT02101138 Hypereosinophilic Syndrome Phase 2 Active, not recruiting October 23, 2019 United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01470859 Idiopathic Parkinson's Disease Not Applicable Completed - China, Shanghai ... More >> Huashan Hospital Affiliated to Fudan University Shanghai, Shanghai, China, 200040 Less <<
NCT02248181 Parkinson Disease COMPLETED - -
NCT02248142 Restless Legs Syndrome COMPLETED - -
NCT00560508 - Completed - -
NCT01470859 - Completed - -
NCT01074450 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 Less <<
NCT01074463 - Completed - -
NCT01066897 Depression PHASE4 TERMINATED 2025-02-13 Stanford University School of ... More >>Medicine, Stanford, California, 94305, United States Less <<
NCT01074450 - Completed - -
NCT01074463 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 Less <<
NCT00601523 Parkinson Disease Phase 3 Completed - -
NCT01066897 Depression PHASE4 TERMINATED 2025-02-13 Stanford University School of ... More >>Medicine, Stanford, California, 94305, United States Less <<
NCT00577460 Parkinson Disease Phase 3 Completed - -
NCT00931944 Amyotrophic Lateral Sclerosis Phase 2 Completed - United States, Arkansas ... More >> University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 United States, California UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center Los Angeles, California, United States, 90095 The Forbes Norris MDA/ALS Research Center San Francisco, California, United States, 94115 United States, Florida University of Miami Miller School of Medicine Miami, Florida, United States, 33136 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Maryland Johns Hopkins University School of Medicine Baltimore, Maryland, United States, 21228 United States, Massachusetts Massachusettes General Hospital Boston, Massachusetts, United States, 02129 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Nebraska Bryan LGH Medical Center East Lincoln, Nebraska, United States, 68506 United States, New York Columbia University, Lou Gehrig MDA/ALS Research Center New York, New York, United States, 10032 SUNY Upstate Medical University Syracuse, New York, United States, 13210 United States, Pennsylvania Penn State Hershey Medical Center Hershey, Pennsylvania, United States, 17033 Drexel University College Of Medicine Philadelphia, Pennsylvania, United States, 19102 University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 United States, Texas University of Texas Health Sciences Center of San Antonio San Antonio, Texas, United States, 78229 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 United States, Virginia University of Virginia Health System Charlottesville, Virginia, United States, 22908 United States, Washington University of Washington Seattle, Washington, United States, 98195 Less <<
NCT00558025 Parkinson Disease Phase 3 Completed - France ... More >> 248.636.3303A Boehringer Ingelheim Investigational Site Aix en Provence, France 248.636.3303B Boehringer Ingelheim Investigational Site Aix en Provence, France 248.636.3303C Boehringer Ingelheim Investigational Site Aix en Provence, France 248.636.3307C Boehringer Ingelheim Investigational Site Bron cedex, France 248.636.3309B Boehringer Ingelheim Investigational Site Clermont Ferrand, France 248.636.3305A Boehringer Ingelheim Investigational Site Créteil, France 248.636.3305B Boehringer Ingelheim Investigational Site Créteil, France 248.636.3313A Boehringer Ingelheim Investigational Site Dijon cedex, France 248.636.3304A Boehringer Ingelheim Investigational Site Evreux, France 248.636.3308B Boehringer Ingelheim Investigational Site Lille cedex, France 248.636.3308C Boehringer Ingelheim Investigational Site Lille cedex, France 248.636.3308D Boehringer Ingelheim Investigational Site Lille cedex, France 248.636.3308E Boehringer Ingelheim Investigational Site Lille cedex, France 248.636.3302A Boehringer Ingelheim Investigational Site Marseille cedex 5, France 248.636.3302B Boehringer Ingelheim Investigational Site Marseille cedex 5, France 248.636.3306B Boehringer Ingelheim Investigational Site Montpellier, France 248.636.3312A Boehringer Ingelheim Investigational Site Rouen, France 248.636.3312B Boehringer Ingelheim Investigational Site Rouen, France 248.636.3311A Boehringer Ingelheim Investigational Site Strasbourg, France 248.636.3301A Boehringer Ingelheim Investigational Site Toulouse cedex, France 248.636.3301B Boehringer Ingelheim Investigational Site Toulouse cedex, France 248.636.3301D Boehringer Ingelheim Investigational Site Toulouse cedex, France Germany 248.636.49006 Boehringer Ingelheim Investigational Site Achim bei Bremen, Germany 248.636.49003 Boehringer Ingelheim Investigational Site Berlin-Steglitz, Germany 248.636.49004 Boehringer Ingelheim Investigational Site Berlin, Germany 248.636.49007 Boehringer Ingelheim Investigational Site Berlin, Germany 248.636.49008 Boehringer Ingelheim Investigational Site Berlin, Germany 248.636.49002 Boehringer Ingelheim Investigational Site Gera, Germany 248.636.49001 Boehringer Ingelheim Investigational Site Karlsruhe, Germany 248.636.49005 Boehringer Ingelheim Investigational Site Unterhaching, Germany Netherlands 248.636.31005 Boehringer Ingelheim Investigational Site `s-hertogenbosch, Netherlands 248.636.31002 Boehringer Ingelheim Investigational Site Geldrop, Netherlands 248.636.31003 Boehringer Ingelheim Investigational Site Helmond, Netherlands 248.636.31006 Boehringer Ingelheim Investigational Site Maastricht, Netherlands 248.636.31004 Boehringer Ingelheim Investigational Site Nijmegen, Netherlands 248.636.31001 Boehringer Ingelheim Investigational Site Sittard, Netherlands Less <<
NCT00558025 - Completed - -
NCT02217332 Chronic Sinusitis With Nasal P... More >>olyps and Eosinophilia Less << Phase 2 Completed - United States, Florida ... More >> ENT Associates of South Florida Boca Raton, Florida, United States, 33487 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21205 United States, Massachusetts Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 United States, North Carolina Wake Research Associates Raleigh, North Carolina, United States, 27612 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania, United States, 15213 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22903 Less <<
NCT02236728 Parkinson Disease COMPLETED - -
NCT02397837 Bipolar Disorder Phase 4 Recruiting October 31, 2018 United States, Massachusetts ... More >> Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Megan Shanahan       mshanahan2@partners.org    United States, New York The Zucker Hillside Hospital Completed Glen Oaks, New York, United States, 11004 Icahn School of Medicine at Mount Sinai Completed New York, New York, United States, 10029 Less <<
NCT00577460 - Completed - -
NCT03430596 Extrapyramidal Syndrome Early Phase 1 Not yet recruiting June 2019 China, Shanghai ... More >> Shanghai Mental Health Center Shanghai, Shanghai, China, 200030 Less <<
NCT01673724 Parkinson's Disease Phase 4 Completed - Korea, Republic of ... More >> Korea University Ansan Hospital Ansan, Korea, Republic of Inje University Busan Paik Hospital Busan, Korea, Republic of Youngnam University Hospital Daegu, Korea, Republic of Kangwon Nat'l University Hospital Kangwon, Korea, Republic of Inje university Sanggye Paik Hospital Seoul, Korea, Republic of Korea University Anam Hospital Seoul, Korea, Republic of Korea University Guro Hospital Seoul, Korea, Republic of Less <<
NCT02248220 Parkinson Disease COMPLETED - -
NCT03521635 Parkinson Disease Phase 4 Recruiting August 14, 2019 China ... More >> Beijing Hospital Recruiting Beijing, China Contact: Haibo Chen    0086 (010) 85136182    chenhbneuro@263.net    The First Afiliated Hospital, Sun Yet-sen University Recruiting Guangzhou, China, 510080 Contact: Ling Chen    +86 13543433955    1678270523@qq.com    Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Recruiting Shanghai, China, 200025 Contact: Shengdi Chen    86-21-64370045/64315052    ruijincsd@126.com    Tianjin Medical University General Hospital Recruiting Tianjin, China, 30052 Contact: Fudong Shi    0086(022)60362255    sfdclinicalstudy@sina.com Less <<
NCT01441284 Essential Tremor Phase 3 Withdrawn(Lack of financial su... More >>pport) Less << December 2018 Hungary ... More >> Department of Neurology, University of Pécs Pécs, Baranya Megye, Hungary, H-7623 Kaposi Mór County Hospital Kaposvár, Somogy Megye, Hungary, H-7400 Less <<
NCT01361009 - Completed - -
NCT01106053 Binge Eating Disorder PHASE3 WITHDRAWN - -
NCT01388478 Alzheimer's Disease Phase 2 Completed - United States, Kansas ... More >> University of Kansas Medical Center Kansas City, Kansas, United States, 66160 Less <<
NCT01651377 Cocaine Addiction ... More >> Cocaine Abuse Cocaine Dependence Substance Abuse Less << Phase 1 Completed - United States, Texas ... More >> Michael E. DeBakey VA Medical Center Houston, Texas, United States, 77030 Less <<
NCT03765138 PTSD MDD Phase 3 Recruiting March 1, 2020 United States, New York ... More >> New York State Psychiatric Institute Recruiting New York, New York, United States, 10032 Contact: Yuval Neria, PhD    646-774-8092    Yuval.neria@nyspi.columbia.edu    Contact: Franklin Schneier, MD    646 823 3863    Franklin.schneier@nyspi.columbia.edu Less <<
NCT02660060 Healthy Not Applicable Completed - Indonesia ... More >> PT Equilab International Jakarta, Indonesia, 12430 Less <<
NCT03681509 Pramipexole E... More >>motions Motivation Reward Dopamine Less << Not Applicable Recruiting September 2019 United Kingdom ... More >> Dept of Psychiatry, University of Oxford Recruiting Oxford, Oxfordshire, United Kingdom, OX3 7JX Contact: Michael Browning, MB.BS    +44 (0)1865 6183161    michael.browning@psych.ox.ac.uk    Principal Investigator: Michael Browning, MB.BS Less <<
NCT00601523 - Completed - -
NCT01361009 - Completed - -
NCT05825235 Anhedonia|Depression PHASE3 RECRUITING 2025-12-31 Region Sk?ne, Lund, Scania, 22... More >>1 85, Sweden Less <<
NCT00349310 Parkinson Disease|Depression COMPLETED 2006-10-01 Boehringer Ingelheim Investiga... More >>tional Site, Innsbruck, 6020, Austria|Boehringer Ingelheim Investigational Site, Wien, 1090, Austria|Boehringer Ingelheim Investigational Site, Wien, 1130, Austria|Hopital Rangueil, Toulouse cedex 9, 31059, France|Hopital Purpan, Toulouse cedex, 31073, France|Neurologisches Fachkrankenhaus fur, Beelitz-Heilstatten, 14547, Germany|Universitatsklinikum Carl Gustav Carus Dresden, Dresden, 01307, Germany|Boehringer Ingelheim Investigational Site, Gera, 07551, Germany|Gertrudis-Kliniken Biskirchen, Leun, 35638, Germany|Boehringer Ingelheim Investigational Site, Unterhaching, 82008, Germany|Parkinson Klinik Wolfach, Wolfach, 77709, Germany|Policlinico di Catania, Catania, 95125, Italy|Azienda Ospedaliera S. Martino, Genova, 16100, Italy|Universita Federico II, Napoli, 80131, Italy|Universita La Sapienza di Roma, Roma, 00161, Italy|Academisch Ziekenhuis Maastricht, Maastricht, 6229 HX, Netherlands|Hospital de Cruces. Neurology, Baracaldo / Bilbao, 48903, Spain|Hospital Clinic i Provincial. Neurology, Barcelona, 08036, Spain|Hospital Puerta del Mar. Neurology, Cadiz, 11519, Spain|Clinica Hildebrand, Brissago, 6614, Switzerland|Hopital Cantonal (HUG), Geneve, 1211, Switzerland|Kantonsspital St. Gallen, St.Gallen, 9007, Switzerland|Boehringer Ingelheim Investigational Site, London, NW3 2QG, United Kingdom|Boehringer Ingelheim Investigational Site, Newark, NG24 4DE, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.73mL

0.95mL

0.47mL

23.66mL

4.73mL

2.37mL

47.32mL

9.46mL

4.73mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories